Clinical trials in Saronno – page 92

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Saronno at a glance

2 862

clinical trials

Research sites1

Quick filters

2 862 trials in Saronno

Open in trial search

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, tacrolimus and pimecrolimus in adults with severe chronic pruritus of unknown origin: a randomized, placebo‑controlled trial

Registered drug

Efficacy and safety of remibrutinib, tacrolimus and pimecrolimus in adults with severe chronic pruritus of unknown origin: a randomized, placebo‑controlled trial

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Pimecrolimus
Sponsor:Novartis Pharma AG

Contact Research Centre

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Peripheral arterial occlusive disease

Not yet recruiting

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:REGN9933
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:BioNTech SE

Contact Research Centre

Colorectal cancer metastatic

Not yet recruiting

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Genmab A/S

Contact Research Centre

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational

Italy

Participants:18–64 years
Substances:LY3841136 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Hypersomnia

Not yet recruiting

Phase 3 Randomized Double‑Blind Study of Pitolisant versus Placebo for Safety and Efficacy in Adults with Idiopathic Hypersomnia

Investigational

Phase 3 Randomized Double‑Blind Study of Pitolisant versus Placebo for Safety and Efficacy in Adults with Idiopathic Hypersomnia

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Pitolisant
Sponsor:Harmony Biosciences Management Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not yet recruiting

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:EXPD-101
Sponsor:Expedition Therapeutics Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:REGN9933
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Pituitary-dependent Cushing's syndrome

Not yet recruiting

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Atumelnant
Sponsor:Crinetics Pharmaceuticals Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

MET deregulation therapy assessment
Second-line combination treatments
EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

Endocrine-responsive breast cancer treatment
Ovarian cancer maintenance therapy
BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

Metastatic renal cancer therapy
Atrial fibrillation management
Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Back to Italy All countries